Table 1 Characteristics of HIV-infected patients newly diagnosed with Kaposi’s sarcoma between 2009 and 2012 in a large community-based primary care network in Kenya
Characteristic | Median (Interquartile range) or Percentage (N = 588) |
|---|---|
Age, years | 35 (30–42) |
Male gender | 357 (61%) |
Documented Symptoms at KS diagnosis | |
Weight loss (self-reported) | 139 (24%) |
Diarrhea (self-reported) | 47 (8%) |
Night sweats | 56 (10%) |
Fever (self-reported or measured) | 107 (18%) |
ECOG performance status Mean (SD) a | 1.34 (0.80) |
ECOG > 1 | 72 (12%) |
Extent of KS on skin | |
Localized to one anatomic area | 115 (20%) |
More than localized | 257 (44%) |
Lymphadenopathy | 72 (12%) |
KS Lesions in oral cavity | 176 (30%) |
Interfering with swallowing | 30 (5.1%) |
GI KS suspected/confirmed | 30 (5.1%) |
Pulmonary KS suspected/confirmed | 51 (8.7%) |
> 1 Ulcerated KS lesion | 69 (12%) |
Edema N | 247 (42%) |
Interfering with function | 26 (4.4%) |
CD4+ T cells, count/μl b | 184 (68–350) |
< 50 | 71 (12%) |
51–100 | 48 (8.2%) |
101–200 | 79 (13%) |
201–350 | 80 (14%) |
> 350 | 92 (16%) |
Antiretroviral therapy (ART) | |
On ART at time of diagnosis | 177 (30%) |
Days on ART among patients on ART at time of KS diagnosis | 119 (42–539) |
On ART > 60 days prior to KS diagnosis | 112 (19%) |
Chemotherapy indication | |
ACTG T1 | 333 (57%) |
WHO “Severe KS” | 92 (16%) |
Education | |
None | 56 (10%) |
Primary | 346 (62%) |
Secondary | 135 (24%) |
Tertiary | 25 (4.4%) |
Travel time to clinic | |
< 30 min | 132 (23%) |
30–60 min | 193 (34%) |
1–2 h | 135 (23%) |
> 2 h | 115 (20%) |
Water piped into home | 74 (13%) |